The most advanced space in the global pharma arena is Biosimilars. This is where cutting edge innovation is providing Superior Biosimilar products covering a wide range of indications/uses.
Keeping in line with our commitment to innovation, we have entered into a JV with Regenix Group to set up a Greenfield  Biosimilar Injectable facility in the name of Regenix Biosciences Ltd.  The plant has been designed and implemented adhering to the EMA Guidelines with a high level of automation and a fully compliant laboratory to start commercial rollout in Q3 2022.

Our Biosimilars Facility

Our Biosimilars facility is situated in the Southern Indian city of Chennai. Setup as a Multidose facility for vials, cartridges, and prefilled syringes, we have an interesting pipeline of products ready to be launched in 2022. We are currently in various stages of Product Development and EMA Audit preparation which we will be triggering in Q1 2022.

Our Biosimilars Features

  • Multidose facility with Vials, Cartridges and Prefilled Syringes
  • Monthly capacity of 3 million Vials
  • Current pipeline of 4 products

Our Products



Prefilled Syringes

Let's Improve Healthcare Together

Prime Pharmaceuticals Pvt. Ltd

B327/328, 3rd Floor,
Chintamani Plaza,
Andheri Kurla Road,
Andheri (East),
Mumbai 400099, INDIA.